Grigorios Kalaitzidis, Omar Ezzedin, Anna Bacchetti, Hussein Moussa, Olwen C Murphy, Angeliki G Filippatou, Henrik Ehrhardt, Eleni Vasileiou, Nicole Pellegrini, Simidele Davis, Morgan Douglas, Kathryn C Fitzgerald, Anna DuVal, Scott Douglas Newsome, Elias S Sotirchos, Bardia Nourbakhsh, Blake E Dewey, Jerry Prince, Shiv Saidha, Peter A Calabresi
{"title":"多发性硬化症中的同名半黄斑萎缩。","authors":"Grigorios Kalaitzidis, Omar Ezzedin, Anna Bacchetti, Hussein Moussa, Olwen C Murphy, Angeliki G Filippatou, Henrik Ehrhardt, Eleni Vasileiou, Nicole Pellegrini, Simidele Davis, Morgan Douglas, Kathryn C Fitzgerald, Anna DuVal, Scott Douglas Newsome, Elias S Sotirchos, Bardia Nourbakhsh, Blake E Dewey, Jerry Prince, Shiv Saidha, Peter A Calabresi","doi":"10.1177/13524585241297816","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Retrograde trans-synaptic degeneration (TSD) following retro-chiasmal pathology, typically retro-geniculate in multiple sclerosis (MS), may manifest as homonymous hemi-macular atrophy (HHMA) of the ganglion cell/inner plexiform layer (GCIPL).</p><p><strong>Objective: </strong>To determine the frequency, association with clinical outcomes, and retinal and radiological features of HHMA in people with MS (PwMS).</p><p><strong>Methods: </strong>In this cross-sectional study, healthy controls (HC) and PwMS underwent retinal optical coherence tomography scanning. For quantitative identification of HHMA, a normalized asymmetry ratio was used, and its normative cutoffs were established from the HC. HHMA PwMS were propensity score matched 1:2 to non-HHMA PwMS. Mixed-effects linear regression models were used in analyses.</p><p><strong>Results: </strong>Based on normative data from 238 HC (466 eyes), 79 out of 942 PwMS exhibited HHMA (8.4%; 143 eyes). Compared to non-HHMA eyes from matched PwMS (158 PwMS; 308 eyes), HHMA eyes had lower average GCIPL (diff: -5.7 μm (95% CI -7.6 to -3.8); <i>p</i> < 0.001) but also inner nuclear layer (diff: -0.9 μm (95% CI -1.6 to -0.1); <i>p</i> = 0.02), and outer nuclear layer (diff: -1.9 μm (95% CI -3.4 to -0.4); <i>p</i> = 0.02) thicknesses; in further analyses, these differences were exclusive to the homonymous side of HHMA. HHMA participants also exhibited higher expanded disability status scale scores (diff: 0.5 (95% CI 0.1 to 0.9); <i>p</i> = 0.02), worse 100% and 2.5% visual acuity scores (diff: -3.2 (95% CI -4.1 to -1.0); <i>p</i> = 0.002, -5.4 (95% CI -7.5 to -3.5); <i>p</i> < 0.001), and higher frequency of microcystoid macular changes (10.1% vs. 3.2%; <i>p</i> = 0.03) compared to non-HHMA participants.</p><p><strong>Conclusions: </strong>HHMA, possibly as a marker of TSD, may signify higher disability in MS.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585241297816"},"PeriodicalIF":4.8000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Homonymous hemi-macular atrophy in multiple sclerosis.\",\"authors\":\"Grigorios Kalaitzidis, Omar Ezzedin, Anna Bacchetti, Hussein Moussa, Olwen C Murphy, Angeliki G Filippatou, Henrik Ehrhardt, Eleni Vasileiou, Nicole Pellegrini, Simidele Davis, Morgan Douglas, Kathryn C Fitzgerald, Anna DuVal, Scott Douglas Newsome, Elias S Sotirchos, Bardia Nourbakhsh, Blake E Dewey, Jerry Prince, Shiv Saidha, Peter A Calabresi\",\"doi\":\"10.1177/13524585241297816\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Retrograde trans-synaptic degeneration (TSD) following retro-chiasmal pathology, typically retro-geniculate in multiple sclerosis (MS), may manifest as homonymous hemi-macular atrophy (HHMA) of the ganglion cell/inner plexiform layer (GCIPL).</p><p><strong>Objective: </strong>To determine the frequency, association with clinical outcomes, and retinal and radiological features of HHMA in people with MS (PwMS).</p><p><strong>Methods: </strong>In this cross-sectional study, healthy controls (HC) and PwMS underwent retinal optical coherence tomography scanning. For quantitative identification of HHMA, a normalized asymmetry ratio was used, and its normative cutoffs were established from the HC. HHMA PwMS were propensity score matched 1:2 to non-HHMA PwMS. Mixed-effects linear regression models were used in analyses.</p><p><strong>Results: </strong>Based on normative data from 238 HC (466 eyes), 79 out of 942 PwMS exhibited HHMA (8.4%; 143 eyes). Compared to non-HHMA eyes from matched PwMS (158 PwMS; 308 eyes), HHMA eyes had lower average GCIPL (diff: -5.7 μm (95% CI -7.6 to -3.8); <i>p</i> < 0.001) but also inner nuclear layer (diff: -0.9 μm (95% CI -1.6 to -0.1); <i>p</i> = 0.02), and outer nuclear layer (diff: -1.9 μm (95% CI -3.4 to -0.4); <i>p</i> = 0.02) thicknesses; in further analyses, these differences were exclusive to the homonymous side of HHMA. HHMA participants also exhibited higher expanded disability status scale scores (diff: 0.5 (95% CI 0.1 to 0.9); <i>p</i> = 0.02), worse 100% and 2.5% visual acuity scores (diff: -3.2 (95% CI -4.1 to -1.0); <i>p</i> = 0.002, -5.4 (95% CI -7.5 to -3.5); <i>p</i> < 0.001), and higher frequency of microcystoid macular changes (10.1% vs. 3.2%; <i>p</i> = 0.03) compared to non-HHMA participants.</p><p><strong>Conclusions: </strong>HHMA, possibly as a marker of TSD, may signify higher disability in MS.</p>\",\"PeriodicalId\":18874,\"journal\":{\"name\":\"Multiple Sclerosis Journal\",\"volume\":\" \",\"pages\":\"13524585241297816\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple Sclerosis Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13524585241297816\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241297816","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:逆行性突触变性(TSD)是多发性硬化症(MS)中典型的逆行性病变,可表现为神经节细胞/内丛状层(GCIPL)的同向半黄斑萎缩(HHMA):目的:确定多发性硬化症(MS)患者出现 HHMA 的频率、与临床结果的关系以及视网膜和放射学特征:在这项横断面研究中,健康对照组(HC)和多发性硬化症患者接受了视网膜光学相干断层扫描。为了定量识别 HHMA,使用了归一化不对称比率,并根据 HC 确定了其标准临界值。HHMA PwMS 与非 HHMA PwMS 按 1:2 进行倾向评分匹配。分析中使用了混合效应线性回归模型:根据 238 名 HC(466 只眼睛)的常模数据,942 名 PwMS 中有 79 名表现出 HHMA(8.4%;143 只眼睛)。与匹配的 PwMS(158 名 PwMS;308 只眼睛)中的非 HHMA 眼睛相比,HHMA 眼睛的平均 GCIPL 更低(差值为-5.7 μL (-5.7 μL )):差异:-5.7 μm (95% CI -7.6 to -3.8);p < 0.001),但核内层(差异:-0.9 μm (95% CI -7.6 to -3.8);p < 0.001)也较低:差异:-0.9 μm (95% CI -1.6 to -0.1);p = 0.02)和核外层(差异:-1.9 μm (95% CI -1.6 to -0.1);p = 0.02):差异:-1.9 μm (95% CI -3.4 to -0.4);p = 0.02);在进一步分析中,这些差异仅出现在 HHMA 的同侧。HHMA 参与者的扩展残疾状况量表评分也更高(diff:0.5 (95% CI 0.1 to 0.9); p = 0.02),100% 和 2.5% 视力评分较差(diff:-P=0.002,-5.4 (95% CI -7.5 to -3.5);P <0.001),与非 HHMA 参与者相比,微囊样黄斑病变的频率更高(10.1% vs. 3.2%;P = 0.03):结论:HHMA可能是TSD的标志,它可能意味着多发性硬化症患者的残疾程度更高。
Homonymous hemi-macular atrophy in multiple sclerosis.
Background: Retrograde trans-synaptic degeneration (TSD) following retro-chiasmal pathology, typically retro-geniculate in multiple sclerosis (MS), may manifest as homonymous hemi-macular atrophy (HHMA) of the ganglion cell/inner plexiform layer (GCIPL).
Objective: To determine the frequency, association with clinical outcomes, and retinal and radiological features of HHMA in people with MS (PwMS).
Methods: In this cross-sectional study, healthy controls (HC) and PwMS underwent retinal optical coherence tomography scanning. For quantitative identification of HHMA, a normalized asymmetry ratio was used, and its normative cutoffs were established from the HC. HHMA PwMS were propensity score matched 1:2 to non-HHMA PwMS. Mixed-effects linear regression models were used in analyses.
Results: Based on normative data from 238 HC (466 eyes), 79 out of 942 PwMS exhibited HHMA (8.4%; 143 eyes). Compared to non-HHMA eyes from matched PwMS (158 PwMS; 308 eyes), HHMA eyes had lower average GCIPL (diff: -5.7 μm (95% CI -7.6 to -3.8); p < 0.001) but also inner nuclear layer (diff: -0.9 μm (95% CI -1.6 to -0.1); p = 0.02), and outer nuclear layer (diff: -1.9 μm (95% CI -3.4 to -0.4); p = 0.02) thicknesses; in further analyses, these differences were exclusive to the homonymous side of HHMA. HHMA participants also exhibited higher expanded disability status scale scores (diff: 0.5 (95% CI 0.1 to 0.9); p = 0.02), worse 100% and 2.5% visual acuity scores (diff: -3.2 (95% CI -4.1 to -1.0); p = 0.002, -5.4 (95% CI -7.5 to -3.5); p < 0.001), and higher frequency of microcystoid macular changes (10.1% vs. 3.2%; p = 0.03) compared to non-HHMA participants.
Conclusions: HHMA, possibly as a marker of TSD, may signify higher disability in MS.
期刊介绍:
Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system.
The journal for your research in the following areas:
* __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics
* __Epidemology and genetics:__ genetics epigenetics, epidemiology
* __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures
* __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management
Print ISSN: 1352-4585